Sustained Remission in an Elderly Patient with Acute Myeloid Leukemia Following Gilteritinib Treatment As Third-Line Salvage Therapy
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Perl A, Altman J, Cortes J, Smith C, Litzow M, Baer M
. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study. Lancet Oncol. 2017; 18(8):1061-1075.
PMC: 5572576.
DOI: 10.1016/S1470-2045(17)30416-3.
View
2.
Molica M, Perrone S, Rossi M
. Gilteritinib: The Story of a Proceeding Success into Hard-to-Treat -Mutated AML Patients. J Clin Med. 2023; 12(11).
PMC: 10253262.
DOI: 10.3390/jcm12113647.
View
3.
Shimony S, Canaani J, Kugler E, Nachmias B, Ram R, Henig I
. Gilteritinib monotherapy for relapsed/refractory FLT3 mutated acute myeloid leukemia: a real-world, multi-center, matched analysis. Ann Hematol. 2022; 101(9):2001-2010.
DOI: 10.1007/s00277-022-04895-8.
View
4.
Dumas P, Raffoux E, Berard E, Bertoli S, Hospital M, Heiblig M
. Gilteritinib activity in refractory or relapsed FLT3-mutated acute myeloid leukemia patients previously treated by intensive chemotherapy and midostaurin: a study from the French AML Intergroup ALFA/FILO. Leukemia. 2022; 37(1):91-101.
DOI: 10.1038/s41375-022-01742-7.
View
5.
Perl A, Martinelli G, Cortes J, Neubauer A, Berman E, Paolini S
. Gilteritinib or Chemotherapy for Relapsed or Refractory -Mutated AML. N Engl J Med. 2019; 381(18):1728-1740.
DOI: 10.1056/NEJMoa1902688.
View